Screener
Pfizer PFE Accrued Manufacturing Costs
Accrued Manufacturing Costs at other companies
Other financials
Where this comes from
Reported directly by Pfizer in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The source filing: Pfizer’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 7:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000078003-26-000054
| (MILLIONS) | March 29,2026 | December 31, 2025 |
|---|---|---|
| Trade accounts payable | 4,506 | 5,240 |
| Dividends payable | — | 2,445 |
| Income taxes payable | 3,130 | 3,103 |
| Accrued compensation and related items | 2,715 | 3,610 |
| Other current liabilities | 20,108 | 19,432 |
| Total current liabilities | 34,348 | 36,984 |
| Long-term debt | 60,565 | 61,641 |
| Pension and postretirement benefit obligations | 1,984 | 2,041 |
Item 1.
FAQ
- What is Pfizer's accrued manufacturing costs?
- Pfizer (PFE) reported accrued manufacturing costs of $2.72B in Q1 2026.
- How has Pfizer's accrued manufacturing costs changed year-over-year?
- Pfizer's accrued manufacturing costs increased by 4.1% year-over-year, from $2.61B to $2.72B.
- What is the long-term trend for Pfizer's accrued manufacturing costs?
- Over 5 years (2020 to 2025), Pfizer's accrued manufacturing costs has grown at a 3.4% compound annual growth rate (CAGR), from $3.05B to $3.61B.
Ask your AI about Pfizer's accrued manufacturing costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude